細胞・遺伝子治療ドラッグデリバリーデバイス市場：製品別、市販薬別-2025-2030年の世界予測

細胞・遺伝子治療ドラッグデリバリーデバイス市場は、2023年に10億8,000万米ドルと評価され、2024年には11億7,000万米ドルに達すると予測され、CAGR 9.78％で成長し、2030年には20億8,000万米ドルに達すると予測されています。

細胞・遺伝子治療ドラッグデリバリーデバイス市場の対象は、遺伝性疾患やその他の主要疾患の治療や修正を目的として、特定の細胞や遺伝子に治療薬を送達する革新的技術です。これらのデバイスは、治療の精度と効率を向上させ、オフターゲット効果を最小化し、治療の可能性を最大化するために不可欠です。用途は腫瘍学、希少遺伝性疾患、免疫学的疾患に及び、主なエンドユーザーは研究機関、病院、バイオ製薬会社などです。成長の原動力となっているのは、細胞治療や遺伝子治療の採用が拡大していること、送達システムの技術的進歩、遺伝子研究への資金提供や投資が増加していることです。治療法の個別化のための人工知能の統合、非ウイルス送達方法の開発、多機能送達プラットフォームを構築するためのテクノロジー企業とバイオテクノロジー企業の連携にビジネスチャンスが生まれます。戦略的提言としては、技術開発のためのパートナーシップ、新興国市場への投資、患者中心の送達ソリューションへの注力などが挙げられます。しかし、この市場は、高いコスト、厳しい規制要件、複雑な製造プロセスといった課題に直面しており、これらはスケーラビリティとアクセシビリティを制限しかねないです。遺伝子マテリアルハンドリング特有の複雑さや専門的なインフラの必要性は、こうした課題をさらに悪化させています。技術革新の機が熟している分野としては、安全性と有効性を向上させるように設計された新規ナノ粒子、脂質ベースのキャリア、生分解性ポリマーの開発が挙げられます。さらに、CRISPRに基づく送達システムの探求とマイクロ流体技術の進歩は、市場の進化に大きな期待を与えます。イノベーションは、送達メカニズムの最適化、製造コストの削減、送達精度の向上に取り組むべきです。市場は急速な技術進化と高い競合を特徴としており、継続的な研究と共同研究が奨励されています。利害関係者は、臨床ニーズに合致し治療成果を高めるイノベーションを促進しながら、規制状況を注意深くナビゲートしなければならないです。

市場力学：急速に進化する細胞・遺伝子治療ドラッグデリバリーデバイス市場の主要市場インサイトを公開

細胞・遺伝子治療ドラッグデリバリーデバイス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患および遺伝性疾患の増加
  • 細胞性および遺伝性疾患の治療薬承認数の増加
  • 高度なドラッグデリバリーシステムを必要とする臨床試験や治療の増加
• 市場抑制要因
  • ドラッグデリバリーデバイスの高コスト
• 市場機会
  • ナノテクノロジーと生体材料の開発の進歩
  • ドラッグデリバリーにおけるAI、ML、センサー技術の活用
• 市場の課題
  • 遺伝子治療の複雑な規制上の課題、医療機器の承認取得の難しさ

ポーターのファイブフォース：細胞・遺伝子治療ドラッグデリバリーデバイス市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：細胞・遺伝子治療ドラッグデリバリーデバイス市場における外部からの影響の把握

外部マクロ環境要因は、細胞・遺伝子治療ドラッグデリバリーデバイス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析細胞・遺伝子治療ドラッグデリバリーデバイス市場における競合情勢の把握

細胞・遺伝子治療ドラッグデリバリーデバイス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス細胞・遺伝子治療ドラッグデリバリーデバイス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞・遺伝子治療ドラッグデリバリーデバイス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨細胞・遺伝子治療ドラッグデリバリーデバイス市場における成功への道筋を描く

細胞・遺伝子治療ドラッグデリバリーデバイス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患および遺伝性疾患の増加
    • 細胞および遺伝性疾患の治療薬の承認件数が増加
    • 高度なドラッグデリバリーシステムを必要とする臨床試験や治療の増加
  • 抑制要因
    • ドラッグデリバリーデバイスの高コスト
  • 機会
    • ナノテクノロジーの進歩と生体材料の開発
    • ドラッグデリバリーにおけるAI、ML、センサー技術の活用
  • 課題
    • 遺伝子治療の複雑な規制上の課題と医療機器の承認の難しさ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 細胞・遺伝子治療ドラッグデリバリーデバイス市場：製品別

• 延長チューブ
• 輸液バッグ
• 静脈カテーテル
• プレフィルドシリンジ
• 滅菌インスリン注射器
• 網膜下注入カニューレ

第7章 細胞・遺伝子治療ドラッグデリバリーデバイス市場市販薬別

• キムリア
• ルクストゥルナ
• プロベンジ
• ストリムヴェリス
• イエスカルタ
• ゾルゲンスマ

第8章 南北アメリカの細胞・遺伝子治療ドラッグデリバリーデバイス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の細胞・遺伝子治療ドラッグデリバリーデバイス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの細胞・遺伝子治療ドラッグデリバリーデバイス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Bausch & Lomb Incorporated
• Becton, Dickinson and Company
• Bluebird bio, Inc.
• Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
• Dendreon Pharmaceuticals LLC.
• Helixmith Co., Ltd.
• Kite Pharma, Inc. by Gilead
• Kolon TissueGene, Inc.
• Novartis AG
• Orchard Therapeutics
• Pfizer, Inc.
• Renova Therapeutics
• Spark Therapeutics, Inc.
• uniQure N.V.
• Vericel Corporation

LIST OF FIGURES

• FIGURE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET RESEARCH PROCESS
• FIGURE 2. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET DYNAMICS
• TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY EXTENSION TUBE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION BAGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS CATHETER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STERILE INSULIN SYRINGE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBRETINAL INJECTION CANNULA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY KYMRIAH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY LUXTURNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PROVENGE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STRIMVELIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY YESCARTA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ZOLGENSMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 28. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 29. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 39. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 40. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 41. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 42. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 43. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 45. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 46. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 47. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 48. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 49. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 51. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 52. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 53. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 55. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 57. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 58. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 59. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 61. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 63. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 64. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 66. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 68. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 70. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 72. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 73. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 74. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 76. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 77. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 78. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 79. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 80. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 82. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 83. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 84. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 85. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 86. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 88. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 89. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 90. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 92. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 95. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 96. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 98. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 100. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 101. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 102. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 104. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 106. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
• TABLE 107. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 108. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

The Cell & Gene Therapy Drug Delivery Devices Market was valued at USD 1.08 billion in 2023, expected to reach USD 1.17 billion in 2024, and is projected to grow at a CAGR of 9.78%, to USD 2.08 billion by 2030.

The scope of the market for cell and gene therapy drug delivery devices focuses on innovative technologies that facilitate the targeted delivery of therapeutic agents to specific cells or genes to treat or modify genetic disorders and other major diseases. These devices are essential for improving the precision and efficiency of therapies and minimizing off-target effects, thereby maximizing therapeutic potential. Applications extend across oncology, rare genetic disorders, and immunological conditions, with key end-users including research institutes, hospitals, and biopharmaceutical companies. Growth is driven by the escalating adoption of cell and gene therapies, technological advancements in delivery systems, and increased funding and investments in genetic research. Opportunities emerge in the integration of artificial intelligence for personalization of therapies, development of non-viral delivery methods, and the collaboration between technology firms and biotech companies to create multi-functional delivery platforms. Strategic recommendations include partnerships for technology development, investing in emerging markets, and focus on patient-centric delivery solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and complex manufacturing processes, which can limit scalability and accessibility. The inherent complexity of genetic material handling and the need for specialized infrastructure further exacerbate these challenges. Areas ripe for innovation include the development of novel nanoparticles, lipid-based carriers, and biodegradable polymers designed to improve safety and efficacy. Additionally, the exploration of CRISPR-based delivery systems and advancements in microfluidic technology offer significant promise for the market's evolution. Innovation should address the optimization of delivery mechanisms, reduction of manufacturing costs, and enhancement of delivery precision. The market is characterized by rapid technological evolution and high competition, encouraging continual research and collaboration. Stakeholders must navigate regulatory landscapes carefully while fostering innovation that aligns with clinical needs and enhances therapeutic outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of chronic and genetic disorders
  • Growing number of drug approvals for treatment of cellular and genetic disorders
  • Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
• Market Restraints
  • High cost of drug delivery devices
• Market Opportunities
  • Advancements in nanotechnology and development of biomaterials
  • Utilization of AI, ML, and sensor technologies for drug delivery
• Market Challenges
  • Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Drug Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Drug Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Drug Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Drug Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Drug Delivery Devices Market

A detailed market share analysis in the Cell & Gene Therapy Drug Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Drug Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Drug Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Drug Delivery Devices Market

A strategic analysis of the Cell & Gene Therapy Drug Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Drug Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC, Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd., Kite Pharma, Inc. by Gilead, Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics, Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Drug Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Products, market is studied across Extension Tube, Infusion Bags, Intravenous Catheter, Pre-Filled Syringe, Sterile Insulin Syringe, and Subretinal Injection Cannula.
• Based on Commercialized Drugs, market is studied across Kymriah, Luxturna, Provenge, Strimvelis, Yescarta, and Zolgensma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of chronic and genetic disorders
    • 5.1.1.2. Growing number of drug approvals for treatment of cellular and genetic disorders
    • 5.1.1.3. Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of drug delivery devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in nanotechnology and development of biomaterials
    • 5.1.3.2. Utilization of AI, ML, and sensor technologies for drug delivery
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell & Gene Therapy Drug Delivery Devices Market, by Products

• 6.1. Introduction
• 6.2. Extension Tube
• 6.3. Infusion Bags
• 6.4. Intravenous Catheter
• 6.5. Pre-Filled Syringe
• 6.6. Sterile Insulin Syringe
• 6.7. Subretinal Injection Cannula

7. Cell & Gene Therapy Drug Delivery Devices Market, by Commercialized Drugs

• 7.1. Introduction
• 7.2. Kymriah
• 7.3. Luxturna
• 7.4. Provenge
• 7.5. Strimvelis
• 7.6. Yescarta
• 7.7. Zolgensma

8. Americas Cell & Gene Therapy Drug Delivery Devices Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Bausch & Lomb Incorporated
• 3. Becton, Dickinson and Company
• 4. Bluebird bio, Inc.
• 5. Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
• 6. Dendreon Pharmaceuticals LLC.
• 7. Helixmith Co., Ltd.
• 8. Kite Pharma, Inc. by Gilead
• 9. Kolon TissueGene, Inc.
• 10. Novartis AG
• 11. Orchard Therapeutics
• 12. Pfizer, Inc.
• 13. Renova Therapeutics
• 14. Spark Therapeutics, Inc.
• 15. uniQure N.V.
• 16. Vericel Corporation